# QTX3034 in Patients With KRAS G12D Mutation

> **NCT06227377** · PHASE1 · RECRUITING · sponsor: **Quanta Therapeutics** · enrollment: 250 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** QTX3034
- **COMBINATION_PRODUCT:** Cetuximab

## Key facts

- **NCT ID:** NCT06227377
- **Lead sponsor:** Quanta Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-05
- **Primary completion:** 2027-04-01
- **Final completion:** 2027-04-01
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06227377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06227377, "QTX3034 in Patients With KRAS G12D Mutation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06227377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*